Mounjaro vs. Farxiga

See how Mounjaro and Farxiga compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Mounjaro is an injectable dual incretin agonist that also drives significant weight loss, while Farxiga is a once-daily pill focused on heart and kidney protection.

  • Farxiga carries FDA approvals for heart failure and chronic kidney disease that Mounjaro does not have.

  • Mounjaro requires a slow multi-step dose increase over several months, while Farxiga starts at a set dose with no titration needed.

Mounjaro vs. Farxiga Drug Summary

Mounjaro

Mounjaro (tirzepatide) is a GIP/GLP-1 receptor agonist injected once weekly under the skin. It is FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is also used off-label for weight loss in people without diabetes.

Farxiga

Farxiga (dapagliflozin) is an SGLT2 inhibitor taken as a once-daily tablet. It is FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease, helping the kidneys remove excess glucose through urine. It is also approved for children 10 and older with type 2 diabetes.

Mounjaro vs. Farxiga Side Effects

Mounjaro

Most common
Nausea (12-18%)
Diarrhea (12-17%)
Decreased appetite (8-11%)
Vomiting (5-9%)

Farxiga

Most common
Female genital mycotic infections (6.9%)
Nasopharyngitis (6.3%)
Urinary tract infections (4.3%)
Back pain (4.2%)

Mounjaro vs. Farxiga Dosage

Mounjaro

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2.5 mg once weekly Weeks 1-4
Maximum dose 15 mg once weekly Week 21 onward
Dose changes 5 increases Every 4 weeks

Farxiga

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once daily At the start
Maximum dose 10 mg once daily If needed
Dose changes 1 increase As tolerated

Mounjaro vs. Farxiga Indications

Mounjaro

Mounjaro is approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is not approved for type 1 diabetes or for weight loss on its own, though many doctors prescribe it off-label for that purpose.

  • Type 2 diabetes glycemic control in adults

  • Type 2 diabetes glycemic control in children 10+

  • Off-label: chronic weight management

  • Not approved for type 1 diabetes

Farxiga

Farxiga is approved for blood sugar control in type 2 diabetes, plus three additional uses Mounjaro does not have: heart failure, chronic kidney disease, and reduced hospitalization risk from heart disease. It is not approved to treat type 1 diabetes or diabetic ketoacidosis.

  • Type 2 diabetes glycemic control in adults and children 10+

  • Heart failure to reduce cardiovascular death and hospitalization

  • Chronic kidney disease to slow decline and reduce death risk

  • Reduce heart failure hospitalization risk in type 2 diabetes with cardiovascular risk factors

Mounjaro vs. Farxiga Pros and Cons

Mounjaro

Mounjaro tends to produce larger blood sugar reductions and more weight loss than oral diabetes pills, but it requires an injection and a gradual dose increase over months. Insurance coverage often hinges on a type 2 diabetes diagnosis, since weight-loss use is off-label.

Pros

  • Greater average blood sugar and weight reduction in trials

  • Only one injection needed per week

  • Dual-hormone mechanism may work when other drugs plateau

Cons

  • Requires self-injection rather than a pill

  • Boxed warning for thyroid C-cell tumor risk

  • Slow titration schedule takes about 5 months to reach top dose

  • Roughly $1,000 to $1,300 per month without insurance, before savings programs

Farxiga

Farxiga is a once-daily pill with a long track record and proven heart and kidney benefits beyond blood sugar control. It causes less weight loss than Mounjaro but carries its own risks, including genital infections and rare serious infections.

Pros

  • Oral tablet, no injections needed

  • Proven to reduce heart failure hospitalization and death

  • Approved to slow chronic kidney disease progression

Cons

  • Less effective for weight loss than Mounjaro

  • Risk of genital yeast infections

  • Rare but serious risk of Fournier's gangrene

  • Not recommended for glycemic control in advanced kidney impairment

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.